Atezolizumab is an anti-PD-L1 immune checkpoint inhibitor that blocks the PD-L1 pathway to enhance antitumor immunity, and it has been studied across multiple solid tumors. Key clinical development data include four completed phase III studies with 3,106 patients with NSCLC, supporting its role as a source treatment in comparative tumor-dynamic modeling. It has been evaluated in non small cell lung cancer as a subcutaneous formulation with rHuPH20 showing non-inferior pharmacokinetic exposure and comparable clinical outcomes to intravenous dosing, and in non squamous non small cell lung cancer as neoadjuvant therapy combined with chemotherapy. It is also being used in colon cancer as adjuvant therapy with chemotherapy for stage III dMMR disease, reflecting expansion beyond lung cancer. In lymphoma, atezolizumab contributed to combination treatment in follicular lymphoma within the FLUORO study alongside obinutuzumab and PET-adapted ultra-low-dose radiotherapy. Overall, recent literature highlights both formulation innovation and broader perioperative/adjuvant immunotherapy applications.
Non-small-cell lung cancer
- Four completed phase III studies in non small cell lung cancer provided the clinical trial dataset for tumor dynamic modeling, totaling 3,106 patients. (PMID:41919988)
- Subcutaneous atezolizumab with rHuPH20 showed non-inferior pharmacokinetic exposure versus intravenous dosing, with comparable clinical outcomes. (PMID:41946650)
- The subcutaneous formulation was developed using data from IMscin001 and related studies, including pharmacokinetic, clinical, safety, and operational evidence. (PMID:41946650)
- Neoadjuvant atezolizumab plus chemotherapy was evaluated in resectable non squamous non small cell lung cancer in an open-label, single-arm phase II trial. (PMID:42003237)
Gastrointestinal cancer
- In stage III dMMR colon cancer, ATOMIC supported adjuvant atezolizumab plus chemotherapy. (PMID:41960736)
- The GI cancer review framed this as a practice-changing immunotherapy approach in the adjuvant setting. (PMID:41960736)
Lymphoma
- Atezolizumab was used in combination therapy for treatment-naïve follicular lymphoma in the FLUORO study. (PMID:41949430)
- The regimen combined checkpoint inhibition with obinutuzumab and PET-adapted ultra-low-dose nodal radiotherapy. (PMID:41949430)
- The FLUORO study reported high efficacy for this multi-modality approach. (PMID:41949430)